Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins
- 1 December 1998
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 33 (6) , 531-536
- https://doi.org/10.1046/j.1365-2559.1998.00505.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapyBritish Journal of Cancer, 1996
- EDITORIAL. REGULATION OF APOPTOSIS BY Bcl-2 AND ITS RELATED PROTEINS: IMMUNOCHEMICAL CHALLENGES AND THERAPEUTIC IMPLICATIONSThe Journal of Pathology, 1996
- EARLY EXPRESSION OF bcl-2 PROTEIN IN THE ADENOMA-CARCINOMA SEQUENCE OF COLORECTAL NEOPLASIAThe Journal of Pathology, 1996
- bcl ‐2 expression in the spectrum of preinvasive breast lesionsCancer, 1996
- Prognostic value of bcl-2 expression in invasive breast cancerBritish Journal of Cancer, 1995
- bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancerBritish Journal of Cancer, 1994
- Bcl-2 and the regulation of programmed cell deathThe Journal of cell biology, 1994
- p53, guardian of the genomeNature, 1992
- The p53 tumour suppressor geneNature, 1991
- Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cellsNature, 1988